Scientific deep-dive

What Is Survodutide? The Glucagon/GLP-1 Dual Agonist in Phase 3

Survodutide is an investigational glucagon/GLP-1 dual agonist with phase 3 obesity data published in 2026. We cover the mechanism, the trial evidence in obesity and MASH, why no head-to-head against tirzepatide exists, and why there is no dose to follow.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
5 min read·3 citations

Survodutide is an investigational once-weekly glucagon/GLP-1 receptor dual agonist from Boehringer Ingelheim and Zealand Pharma. It reached a phase 3 obesity readout published in the New England Journal of Medicine in 2026 [1], on top of a phase 2 dose-finding trial in The Lancet Diabetes & Endocrinology [2] and a separate phase 2 trial in MASH with fibrosis [3]. It is not approved anywhere, and there is no prescription or pharmacy route to it.

The same two receptors as mazdutide

Survodutide and mazdutide target the identical receptor pair — glucagon plus GLP-1 — which makes them the clearest available comparison of how far that combination can go. The difference is regulatory, not mechanistic: mazdutide is approved in China, survodutide is not approved anywhere yet.

Against tirzepatide, the difference is mechanistic. Tirzepatide pairs GLP-1 with GIP; survodutide pairs it with glucagon. The glucagon arm is associated with increased energy expenditure and reduced liver fat rather than additional insulin secretion, which is also why survodutide has been trialed specifically in liver disease [3] — an indication GIP-based drugs are not primarily aimed at.

There is no head-to-head trial. “Survodutide vs tirzepatide” is a popular question with no direct answer: no randomized trial has compared them. Any percentage-versus-percentage comparison you read is assembled from separate trials with different populations, durations and endpoints, and cross-trial comparison of that kind routinely overstates differences. The same caution applies to survodutide vs retatrutide, the other pairing people ask about.

Where the evidence stands

  • Obesity, phase 3: survodutide once weekly in adults with obesity, published in NEJM in 2026 [1].
  • Obesity, phase 2: a randomized, double-blind, placebo-controlled dose-finding trial [2] — the study that established the dose range carried into phase 3.
  • MASH with fibrosis, phase 2: a separate randomized trial [3], reflecting the liver-directed rationale for the glucagon arm.

For how survodutide sits alongside the other compounds in the same wave, see our pipeline roundup covering survodutide, MariTide and ecnoglutide.

There is no survodutide dose to follow

Because it is unapproved, there is no labeled dose and no dose chart. The doses that appear in the phase 2 dose-finding publication are exactly that — the range being tested, under supervision, to determine what should go forward. They are not a regimen, and material sold as “survodutide peptide” is unapproved product of unverified identity rather than a trial drug.

Frequently Asked Questions

No. It is investigational. A phase 3 obesity trial was published in 2026, but there is no marketing authorization and no prescription route.
No randomized trial has compared them directly, so the honest answer is that nobody knows. They also work through different second receptors — glucagon for survodutide, GIP for tirzepatide.
They target the same two receptors, glucagon and GLP-1. The practical difference is regulatory: mazdutide is approved in China for chronic weight management, while survodutide is not approved anywhere.
Glucagon-receptor activation is associated with reduced hepatic fat, which is why a glucagon/GLP-1 dual agonist was trialed in MASH with fibrosis as well as in obesity.

References

  1. 1.le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026. PMID: 42253238.
  2. 2.le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024. PMID: 38330987.
  3. 3.Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024. PMID: 38847460.

What Is Mazdutide? The Obesity Drug Approved in China, Not the US

Mazdutide is a glucagon/GLP-1 dual agonist approved in China for weight management but unavailable in the US. What the approval authorizes, how it differs from tirzepatide and retatrutide, and why an approval abroad doesn't make a US-sold vial legitimate.

6 min read

Mounjaro Body Odor: The Evidence and the One Red Flag

Does Mounjaro cause body odor? Tirzepatide doesn't act on sweat glands — keto breath, dehydration, and dry mouth do. The honest mechanisms and the DKA red flag.

9 min read

What is GIP? GIP Receptor Explained (And Why Mounjaro/Zepbound Activate It Alongside GLP-1)

GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone that drives, with GLP-1, the post-meal incretin effect. Tirzepatide (Mounjaro, Zepbound) is the first approved dual GIP/GLP-1 agonist and beat semaglutide in SURPASS-2.

13 min read

Beyond Wegovy and Zepbound: Three Pipeline GLP-1 Drugs to Watch

Three challenger GLP-1 drugs not made by Lilly or Novo: survodutide (Boehringer Ingelheim and Zealand), maridebart cafraglutide (Amgen's MariTide), and ecnoglutide (Sciwind). This guide covers the published phase 2 and 3 data and mechanisms for each, and where they fit.

11 min read

GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)

A tracker of next-generation GLP-1 and incretin drugs: retatrutide, CagriSema, MariTide, survodutide, amycretin, mazdutide, ecnoglutide and the approved oral pill orforglipron (Foundayo), with stage and peak reported weight loss.

7 min read

Survodutide for Fatty Liver: What the Phase 3 Nature Medicine Trial Shows

In the phase 3 SYNCHRONIZE-MASLD trial, survodutide 6.0 mg cut liver fat by at least 30% in 68.5% of adults at week 48, versus 28.6% on placebo. What that means, what the biopsy data add, and what the trial cannot show about scarring or liver outcomes.

8 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

Pricing Compare

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

Pricing Compare

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

Pricing Compare

Get started →